RCKTW
Rocket Pharmaceuticals, Inc.
Price Chart
Latest Quote
$0.01
Current Price| Open | $0.03 |
| Day High | $0.01 |
| Day Low | $0.00 |
Stock Information
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Book/sh | $2.18 |
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.02 |
| SMA50 | $0.02 |
| RSI | nan |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| YTD | -12.27% |
| 10 Years | -12.27% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.02 | 0 |
| 2026-06-17 | $0.02 | 0 |
| 2026-06-16 | $0.02 | 0 |
| 2026-06-15 | $0.02 | 0 |
| 2026-06-12 | $0.02 | 0 |
| 2026-06-11 | $0.02 | 0 |
| 2026-06-10 | $0.02 | 0 |
| 2026-06-09 | $0.02 | 0 |
| 2026-06-08 | $0.02 | 0 |
| 2026-06-05 | $0.02 | 0 |
| 2026-06-04 | $0.02 | 0 |
| 2026-06-03 | $0.02 | 0 |
| 2026-06-02 | $0.02 | 0 |
| 2026-06-01 | $0.02 | 0 |
| 2026-05-29 | $0.02 | 0 |
| 2026-05-28 | $0.02 | 0 |
| 2026-05-27 | $0.02 | 0 |
| 2026-05-26 | $0.02 | 0 |
| 2026-05-22 | $0.02 | 0 |
| 2026-05-21 | $0.02 | 0 |
| 2026-05-20 | $0.02 | 0 |
| 2026-05-19 | $0.02 | 0 |
đ° Latest News
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Whereâs the Stock Going?
Insider Monkey âĸ 2026-05-20T12:35:35Z
Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M
Insider Monkey âĸ 2026-05-18T04:50:18Z
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Zacks âĸ 2026-05-11T15:50:00Z
Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says
MT Newswires âĸ 2026-05-08T16:18:54ZRocket to sell PRV for $180m to advance gene therapy pipeline
Hospital Management âĸ 2026-04-29T09:34:03Z
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
Zacks âĸ 2026-03-30T16:16:00Z
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
Insider Monkey âĸ 2026-03-29T20:54:29Z
Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy
Simply Wall St. âĸ 2026-03-29T17:03:44Z
Promising Penny Stocks To Consider In March 2026
Simply Wall St. âĸ 2026-03-27T18:05:52Z
Rocket Pharmaceuticals Wins FDA Accelerated Approval for KRESLADI Gene Therapy in Severe LAD-I Kids
MarketBeat âĸ 2026-03-27T14:07:59Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $1,891,000 | $1,886,000 | $1,875,000 | $1,909,000 |
| Total Expenses | $228,516,000 | $273,205,000 | $259,659,000 | $223,843,000 |
| Other Income Expense | $-3,231,000 | - | - | - |
| Net Non Operating Interest Income Expense | $8,624,000 | $14,459,000 | $14,064,000 | $1,980,000 |
| Interest Expense Non Operating | $1,891,000 | $1,886,000 | $1,875,000 | $1,909,000 |
| Operating Expense | $228,516,000 | $273,205,000 | $259,659,000 | $223,843,000 |
| General And Administrative Expense | $86,501,000 | $101,961,000 | $73,317,000 | $58,773,000 |
| Other Operating Expenses | - | - | - | $-500,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Net Interest Income | $8,624,000 | $14,459,000 | $14,064,000 | $1,980,000 |
| Interest Income | $10,515,000 | $16,345,000 | $15,939,000 | $3,889,000 |
| Normalized Income | $-219,892,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Net Income From Continuing And Discontinued Operation | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Total Operating Income As Reported | $-231,747,000 | $-273,205,000 | $-259,659,000 | $-224,343,000 |
| Net Income Common Stockholders | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Net Income | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Net Income Including Noncontrolling Interests | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Net Income Continuous Operations | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Pretax Income | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Special Income Charges | $-3,231,000 | $0 | - | - |
| Interest Income Non Operating | $10,515,000 | $16,345,000 | $15,939,000 | $3,889,000 |
| Operating Income | $-228,516,000 | $-273,205,000 | $-259,659,000 | $-223,843,000 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-206,976,000 | $-247,485,000 | $-236,622,000 | $-213,688,000 |
| Total Unusual Items | $-3,231,000 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $-3,231,000 | $0 | - | - |
| Reconciled Depreciation | $11,025,000 | $9,375,000 | $7,098,000 | $6,266,000 |
| EBITDA (Bullshit earnings) | $-210,207,000 | $-247,485,000 | $-236,622,000 | $-213,688,000 |
| EBIT | $-221,232,000 | $-256,860,000 | $-243,720,000 | $-219,954,000 |
| Diluted NI Availto Com Stockholders | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Restructuring And Mergern Acquisition | $3,231,000 | $0 | - | - |
| Research And Development | $142,015,000 | $171,244,000 | $186,342,000 | $165,570,000 |
| Selling General And Administration | $86,501,000 | $101,961,000 | $73,317,000 | $58,773,000 |
| Other Gand A | $86,501,000 | $101,961,000 | $73,317,000 | $58,773,000 |
Fetched: 2026-06-10
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $212,917,000 | $398,930,000 | $428,270,000 | $424,808,000 |
| Total Assets | $330,449,000 | $527,700,000 | $566,341,000 | $551,807,000 |
| Total Non Current Assets | $137,715,000 | $149,517,000 | $188,119,000 | $187,747,000 |
| Other Non Current Assets | $1,340,000 | $1,362,000 | $1,372,000 | $1,340,000 |
| Non Current Prepaid Assets | $482,000 | $529,000 | $533,000 | $608,000 |
| Goodwill And Other Intangible Assets | $64,304,000 | $64,304,000 | $64,304,000 | $64,878,000 |
| Other Intangible Assets | $25,150,000 | $25,150,000 | $25,150,000 | $25,724,000 |
| Current Assets | $192,734,000 | $378,183,000 | $378,222,000 | $364,060,000 |
| Other Current Assets | $3,805,000 | $5,847,000 | $5,047,000 | $7,666,000 |
| Cash Cash Equivalents And Short Term Investments | $188,929,000 | $372,336,000 | $373,175,000 | $356,394,000 |
| Cash And Cash Equivalents | $77,558,000 | $163,635,000 | $55,904,000 | $140,517,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $24,877,000 | $25,498,000 | $25,042,000 | $22,866,000 |
| Long Term Debt And Capital Lease Obligation | $21,962,000 | $22,641,000 | $22,326,000 | $20,357,000 |
| Current Debt And Capital Lease Obligation | $2,915,000 | $2,857,000 | $2,716,000 | $2,509,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $53,228,000 | $64,466,000 | $73,767,000 | $62,121,000 |
| Total Non Current Liabilities Net Minority Interest | $23,022,000 | $23,782,000 | $25,262,000 | $22,952,000 |
| Other Non Current Liabilities | $1,060,000 | $1,141,000 | $2,936,000 | $2,595,000 |
| Current Liabilities | $30,206,000 | $40,684,000 | $48,505,000 | $39,169,000 |
| Payables And Accrued Expenses | $14,997,000 | $25,883,000 | $35,859,000 | $26,654,000 |
| Payables | $46,000 | - | $13,137,000 | $597,000 |
| Other Payable | $46,000 | - | $13,137,000 | $597,000 |
| Interest Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $277,221,000 | $463,234,000 | $492,574,000 | $489,686,000 |
| Total Equity Gross Minority Interest | $277,221,000 | $463,234,000 | $492,574,000 | $489,686,000 |
| Stockholders Equity | $277,221,000 | $463,234,000 | $492,574,000 | $489,686,000 |
| Gains Losses Not Affecting Retained Earnings | $-31,000 | $66,000 | $319,000 | $-357,000 |
| Other Equity Adjustments | $-31,000 | $66,000 | $319,000 | $-357,000 |
| Retained Earnings | $-1,441,239,000 | $-1,218,116,000 | $-959,370,000 | $-713,775,000 |
| Other | ||||
| Ordinary Shares Number | $108,319,783 | $106,453,818 | $90,282,267 | $79,120,741 |
| Share Issued | $108,319,783 | $106,453,818 | $90,282,267 | $79,123,312 |
| Tangible Book Value | $212,917,000 | $398,930,000 | $428,270,000 | $424,808,000 |
| Invested Capital | $277,221,000 | $463,234,000 | $492,574,000 | $489,686,000 |
| Working Capital | $162,528,000 | $337,499,000 | $329,717,000 | $324,891,000 |
| Capital Lease Obligations | $24,877,000 | $25,498,000 | $25,042,000 | $22,866,000 |
| Total Capitalization | $277,221,000 | $463,234,000 | $492,574,000 | $489,686,000 |
| Additional Paid In Capital | $1,717,408,000 | $1,680,219,000 | $1,450,722,000 | $1,203,074,000 |
| Capital Stock | $1,083,000 | $1,065,000 | $903,000 | $791,000 |
| Common Stock | $1,083,000 | $1,065,000 | $903,000 | $791,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $21,962,000 | $22,641,000 | $22,326,000 | $20,357,000 |
| Current Capital Lease Obligation | $2,915,000 | $2,857,000 | $2,716,000 | $2,509,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,294,000 | $11,944,000 | $9,930,000 | $10,006,000 |
| Current Accrued Expenses | $14,951,000 | $25,883,000 | $22,722,000 | $26,057,000 |
| Goodwill | $39,154,000 | $39,154,000 | $39,154,000 | $39,154,000 |
| Net PPE | $71,589,000 | $83,322,000 | $87,590,000 | $77,645,000 |
| Accumulated Depreciation | $-29,123,000 | $-21,253,000 | $-14,032,000 | $-9,093,000 |
| Gross PPE | $100,712,000 | $104,575,000 | $101,622,000 | $86,738,000 |
| Leases | $7,327,000 | $7,282,000 | $6,723,000 | $589,000 |
| Other Properties | $75,557,000 | $78,741,000 | $77,650,000 | $70,541,000 |
| Machinery Furniture Equipment | $17,828,000 | $18,552,000 | $17,249,000 | $15,608,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $111,371,000 | $208,701,000 | $317,271,000 | $215,877,000 |
| Investments And Advances | - | $0 | $34,320,000 | $43,276,000 |
| Treasury Stock | - | - | $0 | $47,000 |
| Treasury Shares Number | - | - | - | $2,571 |
Fetched: 2026-06-10
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-190,454,000 | $-215,586,000 | $-211,388,000 | $-186,761,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-190,014,000 | $-209,724,000 | $-194,916,000 | $-178,142,000 |
| Cash Flow From Continuing Operating Activities | $-190,014,000 | $-209,724,000 | $-194,916,000 | $-178,142,000 |
| Operating Gains Losses | - | $-1,876,000 | $-364,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-440,000 | $-5,862,000 | $-16,472,000 | $-8,619,000 |
| Investing Cash Flow | $103,767,000 | $131,706,000 | $-98,066,000 | $-69,326,000 |
| Cash Flow From Continuing Investing Activities | $103,767,000 | $131,706,000 | $-98,066,000 | $-69,326,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-67,000 | $0 | $0 | $-47,000 |
| Issuance Of Capital Stock | $0 | $185,739,000 | $208,394,000 | $155,335,000 |
| Financing Cash Flow | $148,000 | $185,739,000 | $208,401,000 | $155,288,000 |
| Cash Flow From Continuing Financing Activities | $148,000 | $185,739,000 | $208,401,000 | $155,288,000 |
| Net Other Financing Charges | $215,000 | - | - | - |
| Net Common Stock Issuance | $-67,000 | $185,739,000 | $208,394,000 | $155,288,000 |
| Common Stock Issuance | $0 | $185,739,000 | $208,394,000 | $155,335,000 |
| Other | ||||
| End Cash Position | $78,898,000 | $164,997,000 | $57,276,000 | $141,857,000 |
| Beginning Cash Position | $164,997,000 | $57,276,000 | $141,857,000 | $234,037,000 |
| Changes In Cash | $-86,099,000 | $107,721,000 | $-84,581,000 | $-92,180,000 |
| Common Stock Payments | $-67,000 | $0 | $0 | $-47,000 |
| Net Investment Purchase And Sale | $104,207,000 | $137,568,000 | $-81,594,000 | $-103,433,000 |
| Sale Of Investment | $380,760,000 | $383,454,000 | $309,326,000 | $272,894,000 |
| Purchase Of Investment | $-276,553,000 | $-245,886,000 | $-390,920,000 | $-376,327,000 |
| Net PPE Purchase And Sale | $-440,000 | $-5,862,000 | $-16,472,000 | $-8,619,000 |
| Purchase Of PPE | $-440,000 | $-5,862,000 | $-16,472,000 | $-8,619,000 |
| Change In Working Capital | $-8,263,000 | $5,671,000 | $13,822,000 | $6,076,000 |
| Change In Other Current Liabilities | $-1,000 | $265,000 | $981,000 | $-5,000 |
| Change In Payables And Accrued Expense | $-10,351,000 | $6,067,000 | $10,147,000 | $9,674,000 |
| Change In Prepaid Assets | $2,089,000 | $-661,000 | $2,694,000 | $-3,593,000 |
| Stock Based Compensation | $37,059,000 | $43,920,000 | $39,406,000 | $31,009,000 |
| Asset Impairment Charge | $262,000 | $0 | $885,000 | $236,000 |
| Amortization Of Securities | $-6,974,000 | $-8,068,000 | $-10,168,000 | $134,000 |
| Depreciation Amortization Depletion | $11,025,000 | $9,375,000 | $7,098,000 | $6,266,000 |
| Depreciation And Amortization | $11,025,000 | $9,375,000 | $7,098,000 | $6,266,000 |
| Depreciation | $11,025,000 | $9,375,000 | $7,098,000 | $6,266,000 |
| Net Income From Continuing Operations | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Proceeds From Stock Option Exercised | - | $0 | $7,000 | $0 |
| Net Business Purchase And Sale | - | $0 | $0 | $42,726,000 |
| Sale Of Business | - | $0 | $0 | $42,726,000 |
| Gain Loss On Investment Securities | - | $-1,876,000 | $-364,000 | - |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Income Tax Paid Supplemental Data | - | - | - | - |
| Other Non Cash Items | - | - | - | - |
Fetched: 2026-06-10